![]() In his lab, they use genetically modified mice to model these neuroimmunological interactions and then develop strategies to re-educate the immune system towards a better outcome. This includes autoimmune diseases, such as neuromyelitis optica, in which the immune system is aberrantly responding to a harmless trigger, as well as Parkinsons and Alzheimer's disease in which the immune system might be reacting to a trigger in the neural environment. Levy is focused on understanding how the immune system and the nervous system interact to cause disease. Levy is the principal investigator on several clinical studies and drug trials for all of these conditions.Īppointed the Research Director of the Division of Neuroimmunology & Neuroinfectious Disease at Massachusetts General Hospital, Dr. Levy has a special interest in patients with superficial siderosis of the central nervous system. MOG Antibody-Associated Disease (MOG-Ab disease) is a recently coined neuro-inlammatory condition that preferentially causes inlammation in the optic nerve but can also cause inlammation in the spinal cord and brain. In addition to neuroimmunology clinics, Dr. Levy specializes in taking care of patients with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease, acute disseminated encephalomyelitis and optic neuritis. The classical complement pathway is activated by C1q interacting with neurons, myelin basic protein (MBP), and myelin oligodendrocytic glycoprotein (MOG). Levy was appointed to the faculty as Assistant Professor at Johns Hopkins where he started the Neuromyelitis Optica Clinic and Research Laboratory and in 2019 he moved to the Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.Ĭlinically, Dr. Levy completed his Johns Hopkins internship in the Osler Medicine program, residency in the Johns Hopkins Neurology program and a fellowship in Neuroimmunology at Johns Hopkins University. MOG antibody disease (MOGAD) is a neurological, immune-mediated disorder in which there is inflammation in the optic nerve, spinal cord and/or brain. He completed the MD/PhD program at Baylor College of Medicine (Houston, TX) with a focus on neuroscience. Michael Levy, MD, PhD, is the Research Director of the Division of Neuroimmunology & Neuroinfectious Disease. ![]() Myelin oligodendrocyte glycoprotein (MOG) is a protein that is located on the surface of myelin sheaths in the central nervous system. To help determine the efficacy of long-term immunotherapy in preventing relapse in patients with MOGAD, we conducted a multicenter retrospective study to determine the rate of. The optimal treatment for reducing relapses is unknown. According to our proposed criteria, MOGAD is typically associated with acute disseminated encephalomyelitis, optic neuritis, or transverse myelitis, and is less commonly associated with cerebral cortical encephalitis, brainstem presentations, or cerebellar presentations. Billing, Insurance & Financial Assistanceĭr. MOG antibody disease (MOGAD) is a neurological, immune-mediated disorder in which there is inflammation in the optic nerve, spinal cord and/or brain. Objective Myelin oligodendrocyte glycoproteinimmunoglobulin G (MOG-IgG) associated disorder (MOGAD) often manifests with recurrent CNS demyelinating attacks. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |